Holen Sie sich die Stockscreener-App
50.05
1.05%
-0.53
Handel nachbörslich:
50.05
Schlusskurs vom Vortag:
$50.58
Offen:
$50.45
24-Stunden-Volumen:
1.57M
Relative Volume:
0.51
Marktkapitalisierung:
$122.87B
Einnahmen:
$43.23B
Nettoeinkommen (Verlust:
$6.79B
KGV:
12.50
EPS:
4.0051
Netto-Cashflow:
$9.17B
1W Leistung:
-2.65%
1M Leistung:
-1.67%
6M Leistung:
-9.72%
1J Leistung:
-6.04%
1-Tages-Spanne:
$49.94
$50.53
1-Wochen-Bereich:
$49.94
$51.63
52-Wochen-Spanne:
$44.62
$60.12
Sanofi Adr Stock (SNY) Company Profile
Vergleichen Sie SNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
50.05 | 123.21B | 43.23B | 6.79B | 9.17B | 4.0051 |
|
LLY
Lilly Eli Co
|
896.53 | 772.28B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.26 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
211.96 | 385.18B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
123.86 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
82.49 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-03-21 | Eingeleitet | Goldman | Neutral |
| 2025-01-30 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Pulmonary Emphysema Market Set to Expand by 2034 with Rising COPD Prevalence and Therapeutic Innovation | DelveInsight - GlobeNewswire Inc.
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Sahm
UPDATE - GlobeNewswire Inc.
Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com Nigeria
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark - Sahm
Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Sahm
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease - Sahm
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times - Sahm
Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study - The Globe and Mail
Sanofi (SNYNF) Gets a Buy from J.P. Morgan - The Globe and Mail
SanofiAmerican Depositary Shares (NQ: SNY - FinancialContent
UBS Reaffirms Their Buy Rating on Sanofi (SNYNF) - The Globe and Mail
Leerink Partners Sticks to Its Buy Rating for Sanofi (SNYNF) - The Globe and Mail
BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals
Sanofi Expands Insulin Savings Program To Cover All US Patients - Sahm
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm
Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability - Sahm
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Sahm
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS® - Ariva
Leerink Partners Sticks to Their Buy Rating for Sanofi (SNY) - The Globe and Mail
What's Going On With Nektar Therapeutics Stock On Thursday? - Sahm
Why Is Sanofi Stock Falling Thursday? - Sahm
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Sahm
New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week - Ariva
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):